Medigen Vaccine Biologics Corporation (TPEX: 6547)

Market Cap	12.36B
Revenue (ttm)	648.17M
Net Income (ttm)	-640.49M
Shares Out	328.73M
EPS (ttm)	-1.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	565,877
Open	37.30
Previous Close	37.10
Day's Range	37.20 - 37.70
52-Week Range	37.05 - 76.60
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6547

Financial Performance

In 2023, Medigen Vaccine Biologics's revenue was 389.62 million, an increase of 6.73% compared to the previous year's 365.04 million. Losses were -1.16 billion, -21.34% less than in 2022.